Biofrontera Inc.

NasdaqCM BFRI

Biofrontera Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -26.35%

Biofrontera Inc. EBITDA Margin is -26.35% for the Trailing 12 Months (TTM) ending September 30, 2024, a 64.13% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Biofrontera Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -73.44%, a -0.59% change year over year.
Biofrontera Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -73.02%, a 23.24% change year over year.
Biofrontera Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -95.12%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: BFRI

Biofrontera Inc.

CEO	Dr. Hermann Luebbert Ph.D.
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	120 Presidential Way
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years